Cidara Therapeutics (CDTX) 10-Q2022 Q1 Quarterly report

Filed: 11 May 22, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absent, accessible, accuracy, arm, attest, bound, Brazil, broader, CI, cohort, confirm, conflict, conjunction, credential, culture, de, deficiency, endpoint, eradication, evasion, fashion, faster, filer, formulary, geopolitical, Geral, healthy, home, ICU, incident, inconsistent, inflation, instability, intramuscular, isolation, Lei, LGPD, licensure, MAA, macroeconomic, median, military, milligram, mindful, multicenter, numerically, offline, online, penetration, persistent, phishing, PIPL, prepaid, prepayment, processor, proper, reveal, Russia, Russian, sNDA, stratified, stuffing, Switzerland, tied, tissue, Ukraine, understanding, Undetected, undiscounted, unrelated, unreliable, upper, volunteer, warrant

Removed: activating, anesthesiologist, Asia, backstopped, BBA, biobanking, Brexit, Britain, centralized, certified, commitment, compute, confiscation, consistency, cooperation, Council, CoV, cyber, Cyberspace, demonstrating, destroyed, diverge, draft, evaluable, expedited, fluconazole, flux, Great, greatest, handle, inappropriately, incompatible, Korea, left, listed, LP, marker, medicinal, MHRA, modeled, offshore, onshore, optional, oral, perception, personally, progressing, promote, proportion, protocol, radiological, referendum, regime, reserve, retention, ruled, sampling, Separately, short, Simplifying, Singapore, South, sponsor, Stonepine, subscription, sufficiently, sustain, Taiwan, tariff, tension, Thailand, umbrella, uncollectible, Union, upheld, usability

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CDTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Cidara Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Preetam Shah, Ph.D., MBA, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 11, 2022						/s/ Preetam Shah, Ph.D., MBA
						Preetam Shah, Ph.D., MBA
						Chief Financial Officer and Chief Business Officer
						(Principal Financial Officer)

The foregoing certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. § 1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.